Literature DB >> 30242126

The effects of CD14 and IL-27 on induction of endotoxin tolerance in human monocytes and macrophages.

Carlene Petes1, Victoria Mintsopoulos1, Renée L Finnen1, Bruce W Banfield1, Katrina Gee2.   

Abstract

Upon repeated exposure to endotoxin or lipopolysaccharide (LPS), myeloid cells enter a refractory state called endotoxin tolerance as a homeostatic mechanism. In innate immune cells, LPS is recognized by co-receptors Toll-like receptor 4 (TLR4) and CD-14 to initiate an inflammatory response for subsequent cytokine production. One such cytokine, interleukin (IL)-27, is produced by myeloid cells in response to bacterial infection. In monocytes, IL-27 has proinflammatory functions such as up-regulating TLR4 expression for enhanced LPS-mediated cytokine production; alternatively, IL-27 induces inhibitory functions in activated macrophages. This study investigated the effects of IL-27 on the induction of endotoxin tolerance in models of human monocytes compared with macrophages. Our data demonstrate that IL-27 inhibits endotoxin tolerance by up-regulating cell surface TLR4 expression and soluble CD14 production to mediate stability of the surface LPS-TLR4-CD14 complex in THP-1 cells. In contrast, elevated basal expression of membrane-bound CD14 in phorbol 12-myristate 13-acetate (PMA)-THP-1 cells, primary monocytes, and primary macrophages may promote CD14-mediated endocytosis and be responsible for the preservation of an endotoxin-tolerized state in the presence of IL-27. Overall, the efficacy of IL-27 in inhibiting endotoxin tolerance in human THP-1 monocytes and PMA-THP-1 macrophages is affected by membrane-bound and soluble CD14 expression.
© 2018 Petes et al.

Entities:  

Keywords:  CD14; NF-κB; Toll-like receptor 4 (TLR4); cytokine action; endotoxin tolerance; inflammation; interleukin-27 (IL-27); lipopolysaccharide (LPS); monocytes/macrophages

Mesh:

Substances:

Year:  2018        PMID: 30242126      PMCID: PMC6231135          DOI: 10.1074/jbc.RA118.003501

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  92 in total

1.  Endocytic pathways regulate Toll-like receptor 4 signaling and link innate and adaptive immunity.

Authors:  Harald Husebye; Øyvind Halaas; Harald Stenmark; Gro Tunheim; Øystein Sandanger; Bjarne Bogen; Andreas Brech; Eicke Latz; Terje Espevik
Journal:  EMBO J       Date:  2006-02-09       Impact factor: 11.598

2.  Lipopolysaccharide-mediated IL-10 transcriptional regulation requires sequential induction of type I IFNs and IL-27 in macrophages.

Authors:  Shankar Subramanian Iyer; Amir Ali Ghaffari; Genhong Cheng
Journal:  J Immunol       Date:  2010-11-01       Impact factor: 5.422

3.  Kinetics of binding of LPS to recombinant CD14, TLR4, and MD-2 proteins.

Authors:  Han Jae Shin; Hayyoung Lee; Jong Dae Park; Hak Chul Hyun; Hyung Ok Sohn; Dong Wook Lee; Young Sang Kim
Journal:  Mol Cells       Date:  2007-08-31       Impact factor: 5.034

Review 4.  Endotoxin recognition and signal transduction by the TLR4/MD2-complex.

Authors:  Katherine A Fitzgerald; Daniel C Rowe; Douglas T Golenbock
Journal:  Microbes Infect       Date:  2004-12       Impact factor: 2.700

5.  TRAM couples endocytosis of Toll-like receptor 4 to the induction of interferon-beta.

Authors:  Jonathan C Kagan; Tian Su; Tiffany Horng; Amy Chow; Shizuo Akira; Ruslan Medzhitov
Journal:  Nat Immunol       Date:  2008-02-24       Impact factor: 25.606

6.  Epigenetic silencing of tumor necrosis factor alpha during endotoxin tolerance.

Authors:  Mohamed El Gazzar; Barbara K Yoza; Jean Y-Q Hu; Sue L Cousart; Charles E McCall
Journal:  J Biol Chem       Date:  2007-07-23       Impact factor: 5.157

7.  Effects of IRF1 and IFN-β interaction on the M1 polarization of macrophages and its antitumor function.

Authors:  Changli Xie; Cuiying Liu; Bitao Wu; Yan Lin; Tingting Ma; Haiyu Xiong; Qin Wang; Ziwei Li; Chenyu Ma; Zhiguang Tu
Journal:  Int J Mol Med       Date:  2016-05-10       Impact factor: 4.101

Review 8.  The Role of IFN-β during the Course of Sepsis Progression and Its Therapeutic Potential.

Authors:  Gorjana Rackov; Rahman Shokri; Melchor Álvarez De Mon; Carlos Martínez-A; Dimitrios Balomenos
Journal:  Front Immunol       Date:  2017-05-08       Impact factor: 7.561

9.  Interleukin (IL)-6 Inhibits IL-27- and IL-30-Mediated Inflammatory Responses in Human Monocytes.

Authors:  Carlene Petes; Mélissa K Mariani; Yawen Yang; Nathalie Grandvaux; Katrina Gee
Journal:  Front Immunol       Date:  2018-02-15       Impact factor: 7.561

Review 10.  Pathophysiology of endotoxin tolerance: mechanisms and clinical consequences.

Authors:  Eduardo López-Collazo; Carlos del Fresno
Journal:  Crit Care       Date:  2013-11-14       Impact factor: 9.097

View more
  5 in total

1.  An alternative model for type I interferon induction downstream of human TLR2.

Authors:  Timo Oosenbrug; Michel J van de Graaff; Mariëlle C Haks; Sander van Kasteren; Maaike E Ressing
Journal:  J Biol Chem       Date:  2020-08-12       Impact factor: 5.157

Review 2.  IL-27, IL-30, and IL-35: A Cytokine Triumvirate in Cancer.

Authors:  Olena Kourko; Kyle Seaver; Natalya Odoardi; Sameh Basta; Katrina Gee
Journal:  Front Oncol       Date:  2019-10-01       Impact factor: 6.244

3.  Characterization of MDCK cells and evaluation of their ability to respond to infectious and non-infectious stressors.

Authors:  Francesca Maria Capellini; Walter Vencia; Massimo Amadori; Giulia Mignone; Erica Parisi; Lucia Masiello; Barbara Vivaldi; Angelo Ferrari; Elisabetta Razzuoli
Journal:  Cytotechnology       Date:  2019-12-04       Impact factor: 2.058

4.  Mismatch between circulating cytokines and spontaneous cytokine production by leukocytes in hyperinflammatory COVID-19.

Authors:  Robin Kahn; Tobias Schmidt; Karan Golestani; Anki Mossberg; Birgitta Gullstrand; Anders A Bengtsson; Fredrik Kahn
Journal:  J Leukoc Biol       Date:  2020-08-13       Impact factor: 6.011

5.  A hyperacute immune map of ischaemic stroke patients reveals alterations to circulating innate and adaptive cells.

Authors:  J R Grainger; C B Lawrence; S Krishnan; C O'Boyle; C J Smith; S Hulme; S M Allan
Journal:  Clin Exp Immunol       Date:  2020-12-09       Impact factor: 5.732

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.